Compare Bristol-Myers Squibb Co (BMY) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Merck & Co., Inc. — how do they compare? Bristol-Myers Squibb Co trades at $64.8 (market cap $132.20B), while Merck & Co., Inc. trades at $130.6 (market cap $317.57B). The key difference: Merck & Co., Inc. is far larger — about 2.4× Bristol-Myers Squibb Co's market cap, and Bristol-Myers Squibb Co pays the higher dividend (3.89%). Which is the better fit depends on your goals.
| BMY | MRK | |
|---|---|---|
Market Cap | $132.20B | $317.57B |
Sector | Health | Health |
52-Week High | $65.89 | $131.84 |
52-Week Low | $42.60 | $77.60 |
Enterprise Value | $166.19B | $360.99B |
Dividend Yield | 3.89% | 2.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Merck (MRK) trades at $128.57, up 0.17% on the day, with a bullish technical signal from moving averages and RSI near oversold levels. Recent earnings have consistently beaten expectations, with Q3 2026 EPS forecast at $2.27. The company's acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline, while 2025 revenue reached $65.01B with a net income margin of 28.07%.
The outlook is positive, supported by strong analyst consensus (67.57% buy ratings) and a price target of $139.90, offering ~8.8% upside. Risks include rising debt-to-asset ratios (36.06% in 2025) and competitive pressures in pharmaceuticals. Investors should weigh growth from strategic acquisitions against execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
